Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,010 across all filing types
Latest filing 2025-04-28 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
2024年度内部控制自我评价报告及相关意见公告
Audit Report / Information Classification · 95% confidence The document is titled as the "2024年度内部控制自我评价报告及相关意见公告" which translates to "2024 Annual Internal Control Self-Evaluation Report and Related Opinions Announcement." It contains detailed descriptions of the company's internal control evaluation, including governance, risk management, internal audit, and control defect standards for both financial and non-financial reporting. The document includes the board of directors' opinion, supervisory board opinion, and auditor's opinion on the internal control effectiveness as of December 31, 2024. The content is comprehensive and includes substantive evaluation results and opinions, not just an announcement of a report or a certification. This type of document is a standalone audit-related report focusing on internal control evaluation and audit opinions, which fits the category of Audit Report / Information (AR). It is not a full annual report (10-K), nor a regulatory filing or announcement. Therefore, the correct classification is AR with high confidence. FY 2024
2025-04-28 Chinese
关于头孢泊肟酯片通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Kangzhi Pharmaceutical Co., Ltd. regarding the approval of their drug Cefpodoxime Proxetil Tablets passing the generic drug consistency evaluation by the National Medical Products Administration. It includes product details, regulatory approval references, market information, and a risk warning to investors. The document is short (1323 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management changes. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category related to compliance and approvals. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-02-27 Chinese
关于变更公司财务总监的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding a change in the company's financial director (CFO). It details the resignation of the previous financial director and the appointment of a new one, including the new director's qualifications and compliance with relevant laws. There are no financial statements, earnings data, or detailed financial analysis present. The document is a formal announcement of a management change, specifically in senior management, which fits the category of Board/Management Information (MANG). The document length is short and focused solely on this personnel change, with no indication of it being a report or presentation.
2025-02-24 Chinese
康芝药业第六届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement from 康芝药业股份有限公司 regarding a resolution passed at the 17th meeting of the 6th Board of Directors. It details the change in the company's Chief Financial Officer, including the resignation of the previous CFO and the appointment of a new CFO, along with the new CFO's resume. The document includes voting results and compliance with relevant laws and company bylaws. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is a formal announcement of a board/management change rather than a full report or financial disclosure. Therefore, it fits the category of Board/Management Information (MANG). The document length is short (1492 characters), and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2025-02-24 Chinese
关于公司完成增加经营范围工商变更登记及《公司章程》备案的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from 康芝药业股份有限公司 regarding the completion of changes to the company's business scope and the filing of the amended Articles of Association with the relevant authorities. It includes details about the new business activities added to the company's license and references prior board and shareholder meeting approvals. The document is relatively short (1452 characters) and serves as a formal notification of these corporate changes rather than a detailed report or financial statement. There is no financial data, audit information, or management discussion present. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-02-17 Chinese
2024年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2024 annual performance forecast (业绩预告) for 康芝药业股份有限公司, covering the period from January 1, 2024 to December 31, 2024. It provides estimated net profit figures and explanations for performance changes. The text explicitly states that the data is preliminary, unaudited, and that the final audited financial data will be disclosed in the 2024 Annual Report. The document length is short (995 characters) and it is a forward-looking earnings forecast rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of periodic financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR), nor is it an announcement of report publication (RPA). Therefore, the correct classification is Earnings Release (ER). FY 2024
2025-01-23 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.